Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Sarah Rowan

Concepts (159)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Hepatitis C
12
2025
250
3.300
Why?
HIV Infections
22
2025
3210
1.940
Why?
Mass Screening
11
2025
1300
1.880
Why?
Hepacivirus
9
2025
236
1.370
Why?
Anti-HIV Agents
7
2025
914
1.280
Why?
Pre-Exposure Prophylaxis
6
2025
272
1.200
Why?
Drug Users
1
2024
43
0.790
Why?
Emergency Service, Hospital
10
2025
2357
0.650
Why?
Substance Abuse Treatment Centers
1
2020
48
0.620
Why?
Tenofovir
2
2020
300
0.590
Why?
Emtricitabine
1
2020
209
0.580
Why?
HIV
4
2025
249
0.510
Why?
Continuity of Patient Care
2
2019
297
0.470
Why?
Coinfection
2
2021
143
0.460
Why?
Choice Behavior
1
2016
179
0.410
Why?
Viral Load
2
2025
525
0.400
Why?
Patient Preference
1
2016
224
0.390
Why?
Sexual Health
2
2024
67
0.380
Why?
Fasciola hepatica
1
2012
2
0.360
Why?
Topography, Medical
1
2012
10
0.360
Why?
Fascioliasis
1
2012
3
0.360
Why?
Anti-Retroviral Agents
1
2014
250
0.350
Why?
Opioid-Related Disorders
1
2020
611
0.350
Why?
Syphilis
2
2024
39
0.350
Why?
RNA, Viral
4
2025
691
0.340
Why?
Hospitalization
4
2025
2468
0.310
Why?
Patient Acceptance of Health Care
2
2024
880
0.310
Why?
Humans
39
2025
145625
0.310
Why?
Patient Compliance
1
2014
587
0.310
Why?
Adult
21
2025
40821
0.300
Why?
Middle Aged
19
2025
36359
0.270
Why?
Antiviral Agents
3
2025
774
0.260
Why?
Male
26
2025
73014
0.250
Why?
Prospective Studies
7
2025
8087
0.250
Why?
Pragmatic Clinical Trials as Topic
2
2024
135
0.250
Why?
Colorado
4
2024
4588
0.240
Why?
Equivalence Trials as Topic
2
2023
34
0.230
Why?
Female
24
2025
79080
0.230
Why?
Drug Utilization Review
1
2025
60
0.220
Why?
Drug Substitution
1
2025
62
0.220
Why?
Prevalence
2
2022
2852
0.210
Why?
HIV-1
3
2021
911
0.200
Why?
Urethritis
1
2023
4
0.200
Why?
Mycoplasma genitalium
1
2023
3
0.200
Why?
Antiretroviral Therapy, Highly Active
1
2025
278
0.200
Why?
Proctitis
1
2023
6
0.200
Why?
Uterine Cervicitis
1
2023
7
0.200
Why?
Mycoplasma Infections
1
2023
17
0.200
Why?
Pelvic Inflammatory Disease
1
2023
12
0.200
Why?
Trench Fever
1
2022
5
0.190
Why?
Bartonella quintana
1
2022
5
0.190
Why?
Endocarditis
1
2022
40
0.180
Why?
Lymphedema
1
2021
22
0.170
Why?
Housing
1
2022
141
0.170
Why?
Cost-Benefit Analysis
1
2024
632
0.160
Why?
Homosexuality, Male
2
2021
231
0.160
Why?
Safe Sex
1
2020
24
0.160
Why?
Focus Groups
1
2024
587
0.160
Why?
Patient Selection
1
2024
720
0.160
Why?
Particulate Matter
1
2023
328
0.160
Why?
Qualitative Research
2
2025
1720
0.150
Why?
Community Health Centers
1
2019
59
0.150
Why?
Health Plan Implementation
1
2020
143
0.150
Why?
Syphilis Serodiagnosis
1
2019
6
0.150
Why?
United States
7
2025
16041
0.150
Why?
Randomized Controlled Trials as Topic
2
2023
1754
0.150
Why?
Treponema pallidum
1
2019
11
0.150
Why?
Hospitals
1
2024
730
0.140
Why?
Darunavir
1
2019
20
0.140
Why?
Health Services Accessibility
2
2024
1101
0.140
Why?
Heterocyclic Compounds, 3-Ring
1
2019
44
0.140
Why?
HIV Protease Inhibitors
1
2019
69
0.140
Why?
Self-Management
1
2021
207
0.140
Why?
Drug Prescriptions
1
2020
290
0.140
Why?
Administration, Oral
1
2020
867
0.130
Why?
HIV Integrase Inhibitors
1
2019
80
0.130
Why?
Public Health Surveillance
1
2018
84
0.130
Why?
Delivery of Health Care, Integrated
1
2020
304
0.120
Why?
Reproductive Health
1
2018
94
0.120
Why?
Time-to-Treatment
1
2019
257
0.120
Why?
Electronic Health Records
1
2024
1208
0.120
Why?
Antibodies, Viral
1
2020
683
0.120
Why?
Referral and Consultation
2
2024
878
0.120
Why?
Treatment Outcome
3
2023
11744
0.120
Why?
Program Evaluation
1
2020
945
0.120
Why?
Ribavirin
1
2016
81
0.120
Why?
Attitude of Health Personnel
1
2024
1212
0.110
Why?
Hepatitis C, Chronic
1
2016
149
0.100
Why?
Sexual and Gender Minorities
1
2019
268
0.100
Why?
Drug Monitoring
1
2018
399
0.100
Why?
CD4 Lymphocyte Count
1
2014
280
0.100
Why?
Time Factors
3
2025
7079
0.100
Why?
Follow-Up Studies
2
2020
5397
0.100
Why?
Algorithms
1
2021
1843
0.100
Why?
Retrospective Studies
6
2025
17291
0.100
Why?
Primary Health Care
2
2023
1768
0.090
Why?
Delivery of Health Care
2
2021
942
0.090
Why?
Enzyme-Linked Immunosorbent Assay
1
2014
845
0.090
Why?
Risk Factors
4
2024
10840
0.090
Why?
Life Cycle Stages
1
2012
38
0.090
Why?
Cohort Studies
2
2019
6045
0.090
Why?
Africa
1
2012
119
0.090
Why?
Adolescent
5
2024
22451
0.090
Why?
Practice Patterns, Physicians'
1
2020
1370
0.080
Why?
Sofosbuvir
2
2022
62
0.080
Why?
Population Surveillance
1
2014
477
0.080
Why?
Travel
1
2012
133
0.080
Why?
Sexual Partners
2
2024
195
0.080
Why?
Socioeconomic Factors
1
2014
1323
0.080
Why?
Young Adult
5
2024
14240
0.070
Why?
Aged
2
2019
26251
0.060
Why?
Sustained Virologic Response
1
2025
47
0.060
Why?
Urban Health Services
1
2025
68
0.060
Why?
Sensitivity and Specificity
2
2021
1992
0.060
Why?
Organizational Case Studies
1
2025
69
0.050
Why?
New Orleans
1
2024
19
0.050
Why?
Demography
1
2024
274
0.050
Why?
Macrolides
1
2023
68
0.050
Why?
Triage
1
2025
243
0.050
Why?
Ambulatory Care Facilities
1
2024
267
0.040
Why?
Drug Resistance, Bacterial
1
2023
185
0.040
Why?
Polyphosphates
1
2022
46
0.040
Why?
Anthropology, Cultural
1
2021
27
0.040
Why?
Intention to Treat Analysis
1
2021
78
0.040
Why?
Nasopharynx
1
2021
72
0.040
Why?
Pregnancy
2
2024
7217
0.040
Why?
Dried Blood Spot Testing
1
2022
129
0.040
Why?
Fluorenes
1
2020
45
0.040
Why?
Multicenter Studies as Topic
1
2022
413
0.040
Why?
Community-Based Participatory Research
1
2022
172
0.040
Why?
Genotype
1
2025
1866
0.040
Why?
Protease Inhibitors
1
2020
103
0.040
Why?
Specimen Handling
1
2021
178
0.040
Why?
Cross-Sectional Studies
2
2021
5875
0.040
Why?
Alanine
1
2020
171
0.040
Why?
Public Health
1
2024
573
0.040
Why?
Saliva
1
2021
256
0.040
Why?
Benzimidazoles
1
2020
189
0.040
Why?
Reagins
1
2019
2
0.040
Why?
Length of Stay
1
2025
1342
0.040
Why?
Oxazines
1
2019
36
0.040
Why?
Odds Ratio
1
2021
1070
0.030
Why?
Research Design
1
2024
1139
0.030
Why?
Immunoglobulin G
1
2022
899
0.030
Why?
Adenine
1
2020
338
0.030
Why?
Chicago
1
2018
62
0.030
Why?
Pyridones
1
2019
210
0.030
Why?
Logistic Models
1
2021
2112
0.030
Why?
Piperazines
1
2019
367
0.030
Why?
Community Health Services
1
2018
229
0.030
Why?
Drug Therapy, Combination
1
2019
1034
0.030
Why?
Risk Assessment
1
2025
3678
0.030
Why?
Physicians
1
2024
954
0.030
Why?
Animals
2
2021
38030
0.030
Why?
Pilot Projects
1
2019
1878
0.020
Why?
Parents
1
2021
1393
0.020
Why?
Anti-Bacterial Agents
1
2023
1935
0.020
Why?
Caregivers
1
2021
1079
0.020
Why?
Child
2
2021
22638
0.020
Why?
Rowan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)